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Abstract 
Therapeutic application of many drugs is often hampered by poor or denied access to intracellular targets. A case in 
point is miltefosine (MT), an orally active antiparasitic drug, which becomes ineffective when parasites develop 
dysfunctional uptake systems. We report here the synthesis of a fluorescent BODIPY-embedding MT analogue with 
appropriate thiol functionalization allowing linkage to the cell-penetrating Tat(48-60) peptide through disulfide or 
thioether linkages. The resulting constructs are efficiently internalized into the otherwise MT-invulnerable R40 
Leishmania strain, resulting in fast parasite killing, hence successful avoidance of the resistance. In the disulfide-
linked conjugate, an additional fluoro tag on the Tat moiety allows to monitor its reductive cleavage within the 
cytoplasm. Terminally differentiated cells such as peritoneal macrophages, impervious to MT unless infected by 
Leishmania, can uptake the drug in its Tat-conjugated form. The results afford proof-of-principle for using CPP 
vectors to avert drug resistance in parasites, and/or for tackling leishmaniasis by modulating macrophage uptake.  
 
Keywords BODIPY, cell-penetrating peptide, miltefosine, dual fluorescent labeling, reversion of resistance, 
monitoring of intracellular drug delivery. 
 
Abbreviations Boc, tert-butyloxycarbonyl; BDP, BODIPY: 4,4-difluoro-4-bora-3a,4a-diaza-s-indacene; CPP, cell-
penetrating peptide; DIEA, diisopropylethylamine; DIPCI, diisopropylcarbodiimide; Fmoc, 9-
fluorenylmethyloxycarbonyl; HBTU, 2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate; 
Mmt, 4-methoxytrityl; MT, miltefosine: hexadecylphosphocholine; Npys, 3-nitro-2-pyridylsulfenyl; TFA, 
trifluoroacetic acid; TIS, triisopropylsilane. 
 
  
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
Introduction 
Poor intracellular accumulation accounts for the failure of not a few drugs (Martinez and Amidon, 2002). Low 
internalization levels may simply reflect low affinity of the drug for cellular membranes (e.g., drugs too hydrophilic 
to traverse a lipid bilayer), but often faulty drug accumulation is due to efflux pumps, or to dysfunctional uptake 
systems, any of which render in practice the cell resistant to the drug. In such cases, using vectors such as cell-
penetrating peptides (CPPs, reviewed in (Koren and Torchilin, 2012; MacEwan and Chilkoti, 2013; Svensen et al., 
2012)) for drug translocation may overcome the resistance, either by impairing cargo detection by ABC transporters 
(Aroui et al., 2009), or by opening an alternate entry route independent of canonical transporters (Lindgren et al., 
2006). CPP-mediated delivery of nucleotides that correct genetic deficiencies (El Andaloussi et al., 2012), of peptides 
that modulate apoptosis (Boohaker et al., 2012; Li et al., 2011), or of drugs with otherwise poor bioavailability (Choi 
et al., 2011; Khafagy el and Morishita, 2012), have been reported and eventually reached clinical trials (Wang and 
Wang, 2012). 
The nature of CPP-cargo linkage, a crucial issue in CPP delivery strategies (Huang et al., 2013; Nasrolahi Shirazi et 
al., 2013), can be roughly divided into covalent and non-covalent. The latter is preferred for large payloads such as 
proteins or, especially, nucleic acids (Crombez et al., 2011; Deshayes et al., 2010; Henriques et al., 2005; Lindberg et 
al., 2013), whose charge complementarity with cationic CPPs is thus usefully exploited. For smaller size cargos like 
pharmaceuticals, however, low yields of non-covalent complex formation often prevent success. In such cases a 
covalent approach, where the CPP is either fused with a cargo sequence (Tyagi et al., 2001) or conjugated by various 
ligation chemistries (Beaudette et al., 2009; Dutot et al., 2009; Steven and Graham, 2008), is favored. Reversible 
strategies relying on disulfide-linked conjugates reductively scissile by cytoplasm redox systems offer distinct 
advantages in this regard (Barnes and Shen, 2009). These CPP-based approaches have been broadly explored for drug 
delivery to tumor cells, but rarely for infectious disease, where they might serve to face the rising threat of 
multiresistant pathogens, exacerbated by the dearth of new antibiotic leads in drug pipelines (Coates and Halls, 2012). 
Miltefosine (MT, hexadecylphosphocholine), originally developed as an antitumoral, finds now a major therapeutic 
application as the first successful oral drug against leishmaniasis (reviewed in (Dorlo et al., 2012)). With an annual 
incidence of nearby 2 million people worldwide, and approximately 50,000 casualties in recent outbreaks in Sudan 
and Ethiopia, leishmaniasis ranks second only to malaria among protozoan diseases (Alvar et al., 2012) and remains a 
formidable health challenge. An effective vaccine is proving elusive, and chemotherapy continues to rely on dated, 
rather toxic antimonials beset by resistance in endemic foci (Chappuis et al., 2007; Rijal et al., 2013). Together with 
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MT, amphotericin B (usually in liposomal formulation) or paromomycin are recent additions to first-line anti-
leishmanial agents (den Boer et al., 2009) but limited to combination therapies also threatened by emerging resistance 
(Garcia-Hernandez et al., 2012). Clearly, novel therapeutic approaches are required to redress such a discouraging 
scenario. 
MT is a good example of an effective drug with non-optimal absorption profile. Upon MT exposure Leishmania 
promastigotes develop a resistant phenotype featuring poor MT accumulation (Perez-Victoria et al., 2003), due to the 
failure of the sole uptake system known for the parasite, i.e., the aminophospholipid translocase LdMT (Leishmania 
donovani miltefosine transporter) (Seifert et al., 2007) and its regulatory subunit LdRos. As a tool for facilitating MT 
internalization, hence defeating this MT resistance in Leishmania, we have explored the use of Tat(48-60), one of the 
most representative cell-penetrating peptides (CPPs) (Luque-Ortega et al., 2012).  
To monitor the distribution and localization of MT within the parasites, a BODIPY (BDP)-containing analog, 
adequately functionalized for conjugation to Tat(48-60), was required. Earlier work had determined the optimal 
location within the MT alkyl chain for a BDP moiety (Hornillos et al., 2008; Hornillos et al., 2006) in terms of 
preserving both leishmanicidal activity and recognition by the Leishmania uptake system, and also shown that both 
properties were unaffected by incorporation of an ω-thiol group. These preliminary results inspired the development 
of MT-BDP-SH (1), whose synthesis is described here in detail for the first time. Subsequent conjugation of 1 to 
Tat(48-60), via either disulfide or thioether bonds, enabled the intracellular delivery of 1 and, for MT-resistant strains, 
the overcoming of the resistance (Luque-Ortega et al., 2012). The conjugates were mostly built in the solid phase, by 
judicious choice of protecting groups on two strategic residues (Schemes 1 and 3). In addition to the BDP moiety 
embedded in 1, the disulfide-based conjugate was labeled at the Tat peptide moiety with Quasar 640, a non-
overlapping fluorophore so that redox scission inside the parasite resulted in different fluorescent patterns illustrating 
the intracellular localization of the MT-like moiety and its Tat vector.  
The main advantage of the present approach is the ability to turn into susceptible the hitherto resistant parasite cells 
and thus overcome the limitations and broaden the therapeutic scope of the drug. In addition, conjugation to Tat 
enables MT uptake into terminally differentiated cells such as non-infected macrophages, hence expanding the range 
of MT cellular targets, hitherto limited to tumor cells. This in turn can pave the way for modulating macrophage 
functionality, a key step towards immune system readjustment, with many possibilities to follow. 
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Materials and Methods 
MT-BDP-SH (1) synthesis.  
All reactions were carried out under Ar. Commercial reagents were used as received. Solvents were purified by 
standard methods and deoxygenated thoroughly with Ar bubbling prior to use. Yields refer to the isolated pure 
compound. Analytical TLC was carried out on Merck 60F 254, 0.25 mm precoated silica gel plates. Flash column 
chromatography was performed on Merck 60 silica gel, 230400 mesh, 0.0400.063 mm. HPLC analyses were done 
on an Agilent 1100 system equipped with an Eclipse C18 reverse phase column (4.6150 mm, 5 μm, Agilent) and a 
diode array detector. 
1
H and 
13
C NMR spectra were recorded on Bruker-300 and Varian 400 spectrometers, 
respectively. Chemical shifts are reported in parts per million (ppm), using the 
1
H signal of (trace) chloroform or the 
13
C signal of CDCl3 ( 7.26 and 77.0, respectively) as internal references. Abbreviations: s (singlet), d (doublet), t 
(triplet), q (quartet), m (complex multiplet), b (broad). Assignments are based on COSY, HSQC and HMBC 
experiments. IR spectra (in cm
1
) were recorded on Perkin-Elmer 681 and FT-Spectrum One spectrometers. Low 
resolution mass spectra were recorded by electron impact (70 eV) in a Hewlett-Packard 5973 spectrometer in the 
direct injection mode, or by electrospray ionization in a Hewlett-Packard 1100 spectrometer in the positive mode 
(ESI+). High resolution mass spectra were registered in an AutoSpec Micromass (Waters) instrument in the L-SIMS 
mode using Cs+ (30 kV) in m-NBA matrix, with PEG as internal standard. UV-VIS absorption spectra were recorded 
on Varian CARY-3E or Perkin Elmer Lambda-2 spectrophotometers. Stationary fluorescence excitation and emission 
spectra were recorded in an ISS PC1 photon counting spectrofluorimeter and corrected for instrumental factors. 
Relative fluorescence quantum yields were determined, with an uncertainty of 10-20%, by reference to that of the 
BODIPY dye PM567, Φf = 0.91 in methanol at 20 ºC (Saugar et al., 2007). 
Synthetic route to 1 
a. 8-[6’-(3’’-Bromopropyl)-1’,3’,5’,7’-tetramethyl-4’,4’-difluoro-4’-bora-3’a,4’a-diaza-s-indacen-2’-yl]octyl tri-
fluoroacetate (4) (Scheme 2)  
Phosphorus oxychloride (167 mg, 102 µL, 1.09 mmol) was added under Ar to a stirred solution of pyrroles 2 and 3 
(236 and 380 mg, respectively; 1.09 mmol each; see Supporting Information for details on their synthesis) in CH2Cl2 
(150 mL). After stirring for 5 h at r.t. N,N-diisopropylethylamine (DIEA, 950 µL, 5.45 mmol) and, after 5 min, 
BF3.OEt2 (685 µL, 5.45 mmol) were added. After 5 min, the same amounts of DIEA and BF3.OEt2 were added again, 
and the mixture was further stirred for 20 min. After workup, the crude product was purified by column 
chromatography (silica gel, hexane EtOAc 9:1). Red solid, yield 725 mg, 85%. TLC (hexaneEtOAc 4:1): Rf = 
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0.60; 
1
H NMR (400 MHz, CDCl3, see Supporting Information for carbon numbering):  -3 to H-
7), 1.74 (q, J = 6.9 Hz, 2H, H-2), 1.99 (q, Jobs = 6.9 Hz, 2H, H-2’’), 2.15, 2.19 (two s, 3H each, CH3-C1’, CH3-C7’), 
2.35 (t, J = 7.5 Hz, 2H, H-8), 2.48, 2.49 (two s, 3H each, CH3-C3’, CH3-C5’), 2.54 (t, J = 7.4 Hz, 2H, H-1’’), 3.41 (t, J 
= 6.4 Hz, 2H, H-3’’), 4.34 (t, J = 6.7 Hz, 2H, H-1), 6.96 (s, 1H, H-8’); 13C NMR (100 MHz, CDCl3):  9.6, 9.7 (CH3-
C1’, CH3-C7’), 12.6, 12.8 (CH3-C3’, CH3-C5’), 22.3 (C-1’’), 24.0 (C-8), 25.4, 29.0, 29.2, 29.3, 30.0 (C-3 to C-7), 
28.0 (C-2), 32.9 (C-2’’), 33.2 (C-3’’), 68.2 (C-1), 115.9 (CF3), 118.8 (C-8’), 127.7, 130.6, 132.1, 132.8, 137.1, 137.6 
(C-1’, C-2’, C-6’, C-7’, C-7’a, C-8’a), 154.0, 155.9 (C-3’, C-5’), 157.7 (C=O); FT IR (KBr) max: 2930, 2858, 1785 
(C=O), 1606, 1473, 1403, 1229, 1065 cm ; EI MS, m/z (%): 592 [M

] (not observed), 496 (28), 476 (37), 381 
7H14OCOCF3] (100).  
 
b. 8-[6’-(3’’-Quinol-2’’’-ylthiopropyl)-1’,3’,5’,7’-tetramethyl-4’,4’-difluoro-4’-bora-3’a,4’a-diaza-s-indacen-2’-
yl]octan-1-ol (Scheme 2).  
A previously described method was used (Imahori et al., 2001). Briefly, a solution of 2-quinolinethiol (76 mg, 0.47 
mmol) and NaOMe (25 mg, 0.47 mmol) in MeOH (10 mL) was stirred for 30 min at r.t. Compound 4 was then added 
and the resulting solution was refluxed for 2 h. The solvent was removed under vacuum and the residue was extracted 
with MeCN (320 mL), the combined extracts were vacuum evaporated and the residue was purified by column 
chromatography (silica gel, hexaneEtOAc 7:3). Red solid, yield 65 mg, 95%. TLC (hexaneEtOAc 1:1): Rf = 0.50; 
1
H NMR (400 MHz, CDCl3, see Supporting Information for carbon numbering):  m, 8H, H-3 to H-6), 1.41 
(m, 2H, H-7), 1.55 (q, J = 6.9 Hz, 2H, H-2), 1.93 (q, Jobs = 7.4 Hz, 2H, H-2’’) 2.14, 2.17 (two s, 3H each, CH3-C1’, 
CH3-C7’), 2.33 (t, J = 7.5 Hz, 2H, H-8), 2.48, 2.51 (two s, 3H each, CH3-C3’, CH3-C5’), 2.57 (t, J = 7.6 Hz, 2H, H-
1’’), 3.34 (t, J = 7.3 Hz, 2H, H-3’’), 3.62 (t, J = 6.6 Hz, 2H, H-1), 6.93 (s, 1H, H-8’), 7.19 (d, J = 8.6 Hz, 1H, H-3’’’), 
7.42 (m, 1H, H-7’’’), 7.63 (m, 1H, H-6’’’), 7.70 (dd, J = 8.1, 1.0 Hz, 1H, H-8’’’), 7.88 (d, J = 8.7 Hz, 1H, H-4’’’), 
7.93 (d, J = 8.0 Hz, 1H, H-5’’’); 13C NMR (100 MHz, CDCl3):  9.5, 9.6 (CH3-C1’, CH3-C7’), 12.7, 12.8 (CH3-C3’, 
CH3-C5’), 23.2 (C-1’’), 24.0 (C-8), 25.7, 29.2, 29.3, 29.3, 29.4, 29.6. 30.0 (C-3 to C-7, C-2’’, C-3’’), 32.7 (C-2), 62.9 
(C-1), 118.6 (C-8’), 120.9 (C-3’’’), 125.2 (C-7’’’), 125.8 (C-4’’’a), 127.5, 127.8 (C-5’’’, C-8’’’), 129.7 (C-6’’’), 
135.4 (C-4’’’), 127.7, 130.4, 132.2, 132.5, 137.0, 137.2 (C-1’, C-2’, C-6’, C-7’, C-7’a, C-8’a), 148.0 (C-8’’’a), 154.4, 
155.3 (C-3’, C-5’), 159.0 (C-2’’’); EI MS, m/z (%): 577 [M HF)] (100), 396 (63), 
370 (40), 301 (95), 273 (65).  
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c. 8-[6’-(3’’-Quinol-2’’’-ylthiopropyl)-1’,3’,5’,7’-tetramethyl-4’,4’-difluoro-4’-bora-3’a,4’a-diaza-s-indacen-2’-
yl]octylphosphocholine (6) (Scheme 2) 
Trimethylamine (ca. 2 mL) was condensed into a solution of alcohol 5 (63 mg, 0.11 mmol) in MeCN (10 mL) in an 
open pressure tube at –78 ºC under Ar. 2-Chloro-1,3,2-dioxaphospholane-2-oxide (20 µL, 0.22 mmol) was then added 
to the cooled solution and the tube was closed and left 3 h at r.t. and 4 h at 80 ºC. After cooling back to r.t. the reactor 
was opened, the solvent and the unreacted trimethylamine were vacuum-evaporated, the residual solid was dissolved 
in THFH2O 9:1 (10 mL), and Amberlite MB-3 was added until resin saturation. The mixture was filtered, the 
separated solid was washed with MeOH (310 mL), the filtrate and washings were collected, the solvent was 
evaporated, and the residual solid was purified by column chromatography (silica gel, first eluting with CHCl3-MeOH 
9:1, for the separation of non-polar products, and then with CHCl3-MeOH-H2O 65:25:5). Red solid, yield 35 mg, 
43%. TLC (CHCl3-MeOH-H2O 65:25:5): Rf = 0.40; 
1
H NMR (400 MHz, CD3OD, see Supporting Information for 
carbon numbering):  -3 to H-6), 1.39 (m, 2H, H-7), 1.62 (q, J = 6.7 Hz, 2H, H-2), 1.90 (q, Jobs = 
7.4 Hz, 2H, H-2’’), 2.15, 2.16 (two s, 3H each, CH3-C1’, CH3-C7’), 2.37 (t, J = 7.4 Hz, 2H, H-8), 2.42, 2.43 (two s, 
3H each, CH3-C3’, CH3-C5’), 2.57 (t, J = 7.4 Hz, 2H, H-1’’), 3.19 (s, 9H, N(CH3)3), 3.29 (t, J = 7.5 Hz, 2H, H-3’’), 
3.59 (m, 2H, CH2N), 3.86 (td, J = 6.7, 6.5 Hz, 2H, H-1), 4.22 (m, 2H, OCH2CH2N), 7.19 (s, 1H, H-8’), 7.22 (d, J = 
8.7 Hz, 1H, H-3’’’), 7.41 (ddd, J = 8.1, 7.0, 1.2 Hz, 1H, H-7’’’), 7.60 (ddd, J = 8.5, 7.0, 1.5 Hz, 1H, H-6’’’), 7.75 (dd, 
J = 8.1, 1.3 Hz, 1H, H-8’’’), 7.80 (m, 1H, H-5’’’), 7.97 (d, J = 8.7 Hz, 1H, H-4’’’); 13C NMR (100 MHz, CD3OD):  
9.6, 9.7 (CH3-C1’, CH3-C7’), 12.9 (CH3-C3’, CH3-C5’), 24.0 (C-1’’), 24.8 (C-8), 27.0, 30.0, 30.5, 30.5, 30.7, 31.0, 
31.3, 31.8, 31.9 (C-2 to C-7, C-2’’, C-3’’), 54.65, 54.69, 54.72 (N(CH3)3), 60.3 (d, J = 4.7 Hz, OCH2CH2N), 66.9 (d, 
J = 6.1 Hz, C-1), 67.5 (b s, CH2N), 120.8 (C-8’), 121.9 (C-3’’’), 126.5, 130.9 (C-6’’’, C-7’’’), 127.4 (C-4’’’a), 128.7, 
128.9 (C-5’’’, C-8’’’), 130.2, 131.6, 133.8, 134.0, 139.1, 139.2 (C-1’, C-2’, C-6’, C-7’, C-7a’, C-8’a), 136.9 (C-4’’’), 
149.5 (C-8’’’a), 155.5, 156.1 (C-3’, C-5’), 160.7 (C-2’’’); ESI+ MS, m/z: 743 [M + H+]. 
d. 8-[6’-(3’’-Mercaptopropyl)-1’,3’,5’,7’-tetramethyl-4’,4’-difluoro-4’-bora-3a’,4a’-diaza-s-indacen-2’-yl]octyl-
phosphocholine (1, HS-BDP-MT) (Scheme 2) 
 A described deprotection procedure was applied (Nakamura et al., 2002; Zhang and Matteucci, 1999). NaBH3CN (15 
mg, 0.236 mmol) was added at r.t. to a solution of 6 (35 mg, 0.047 mmol) in HOAc (0.9 mL) , and the mixture was 
stirred for 2 h. Water (0.7 mL) was then added, and the reaction mixture was further stirred for 1 h. After the 
subsequent workup, the isolated residue was purified by column chromatography (silica gel, first eluting with CHCl3-
MeOH 9:1, for the separation of non-polar products, and then with CHCl3-MeOH-H2O 65:25:5). Red solid, mp 199-
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201 ºC, yield 27 mg, 94%. TLC (chloroform-methanol-water 65:25:5): Rf = 0.40; 
1
H NMR (400 MHz, CD3OD, see 
Supporting Information for carbon numbering):  1.301.38 (m, 8H, H-3 to H-6), 1.42 (m, 2H, H-7), 1.64 (q, J = 6.7 
Hz, 2H, H-2), 1.72 (q, Jobs = 7.3 Hz, 2H, H-2’’), 2.17, 2.18 (two s, 3H each, CH3-C1’, CH3-C7’), 2.38 (t, J = 7.5 Hz, 
2H, H-8), 2.42, 2.43 (two s, 3H each, CH3-C3’, CH3-C5’), 2.50 (m, 4H, H-1’’, H-3’’), 3.22 (s, 9H, N(CH3)3), 3.63 (m, 
2H, CH2N), 3.87 (td, J = 6.7, 6.5 Hz, 2H, H-1), 4.25 (m, 2H, OCH2CH2N), 7.24 (s, 1H, H-8’); 
13
C NMR (100 MHz, 
CD3OD):  9.6 (CH3-C1’, CH3-C7’), 12.8, 12.9 (CH3-C3’, CH3-C5’), 23.4, 24.6 (C-1’’, C-3’’), 24.8 (C-8), 30.4, 30.5, 
30.7, 31.3, 31.8, 31.9 (C-2 to C-7), 35.5 (C-2’’), 54.68, 54.72, 54.75 (N(CH3)3), 60.3 (d, J = 4.9 Hz, OCH2CH2N), 
66.9 (d, J = 5.9 Hz, C-1), 67.5 (b s, CH2N), 120.8 (C-8’), 130.2, 131.6, 133.8, 134.0, 139.1, 139.2 (C-1’, C-2’, C-6’, 
C-7’, C-7’a, C-8’a), 155.4, 156.1 (C-3’, C-5’); FT IR (KBr) max: 3435, 2927, 2855, 1606, 1474, 1228 (P=O), 1069 
(P-O-C), 969 cm ; ESI
+
 MS, m/z: 616 [M + H
+
], 638 [M + Na
+
]; HR MS (peak matching): calculated for 
C29H49BF2N3O4PS+H 616.3321; found 616.3319; HPLC (reverse phase C18 column, MeOHH2O 9:1, 1.2 mL min
1
, 
anal 280, 380 and 503 nm: Rt = 2.63 min (100% purity); UV-VIS (EtOH) max (nm) (, M  cm ): 380 (10000), 502 
(35000), 529 (82000); emission (EtOH, corrected): max  538 nm; fluorescence quantum yield: 0.70 (10  M solution in 
EtOH).  
 
Peptide and conjugate synthesis 
 Fmoc-protected amino acids, HBTU and Fmoc-Rink-amide resin were from Iris Biotech (Marktredwitz, Germany). 
HPLC-grade CH3CN and peptide synthesis-grade DMF, CH2Cl2, DIEA and TFA were from Carlo Erba (Sabadell, 
Spain). All other reagents were of the highest quality commercially available from Sigma-Aldrich (Madrid, Spain). 
The Tat(48-60) peptide was assembled in an ABI433 peptide synthesizer (Applied Biosystems, Foster City, CA) 
running Fmoc (FastMoc) SPPS protocols at 0.1 mmol scale. Side chains were protected with Boc (Lys), N
G
-2,2,4,6,7-
pentamethyldihydrobenzofuran-5-sulfonyl (Arg) and trityl (Gln) groups. The canonic sequence was elongated at the 
N-terminus with a Lys residue protected at the side chain with the Mmt group. Eight-fold excess of Fmoc-L-amino 
acids and HBTU, in the presence of a double molar amount of DIEA, were used for the coupling steps, with DMF as 
solvent. Resin-bound peptides were fully deprotected and cleaved by treatment with TFA/H2O/TIS (95:2.5:2.5 v/v, 90 
min. Analytical reversed-phase HPLC was performed on C18 columns (4.6 × 50 mm, 3 μm, Phenomenex, Torrance, 
CA) in a model LC-2010A system (Shimadzu, Kyoto, Japan). Solvent A was 0.045% (v/v) TFA in water, solvent B 
was 0.036% (v/v) TFA in CH3CN. Elution was done with linear gradients (see Supporting Information) of solvent B 
into A over 15 min at 1 mL/min flow rate, with UV detection at 220 nm. Preparative HPLC was performed on C18 (10 
× 250 mm, 10 μm, Phenomenex) in a Shimadzu LC-8A instrument. Solvents A and B were 0.1% TFA (v/v) in water 
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and CH3CN, respectively, and elution was again with linear gradients of solvent B into A over 30 min, at 7 mL/min 
flow rate with UV detection at 220 nm. Fractions of satisfactory purity (>95%) by analytical HPLC were pooled and 
lyophilized. Purified peptides and conjugates were characterized for identity by MS as indicated below.  
 
Synthesis of Quasar 670-Lys(Cys-S-BDP-MT)Tat (7) 
One half of the Fmoc-Lys(Mmt)-elongated Tat peptide-resin (50 mol) was treated with piperidine/DMF (1:4 v/v, 1 
+ 20 min) to remove the Fmoc group, then acylated with Quasar 670 (indo-5-carbocyanine N-ethyl-N'-hexanoic acid; 
74 mg, 150 mol) with DIPCI (23 L, 150 mol) activation in CH2Cl2 for 1 h. The peptide-resin was treated with 1% 
TFA/ CH2Cl2 to remove the Mmt group, neutralized with 5% DIEA/ CH2Cl2 and Boc-Cys(Npys) (53 mg, 150 mol) 
was coupled at the Lys –amino function, with DIPCI activation (150 mol) in CH2Cl2 for 1 h. Deprotection (except 
the Npys group) and cleavage of the peptide-resin were done with TFA/H2O/TIS (95:2.5:2.5 v/v), for 90 min, 
followed by HPLC purification and lyophilization. Next, the Quasar 670-Lys[Cys(Npys)]Tat peptide (4 mg, 1.6 
mol) was dissolved in 5 mL H2O, pH was adjusted to 5.0, and 24 L of a 65 mM solution of 1 (1.6 mol) in 
methanol was added. The reaction mixture was stirred at r.t. until HPLC analysis showed complete conversion to 7, 
then diluted with 5 mL H2O, purified by HPLC and lyophilized to give 2.8 mg of conjugate 7, amounting to 60% 
yield in the disulfide formation and purification steps. 7 was characterized by analytical HPLC and MS (Figures S3 
and S4, Supporting Information).  
 
Synthesis of Ac-Lys(COCH2-S-BDP-MT)Tat (8).  
The other half (50 mol) of the Fmoc-Lys(Mmt)-elongated Tat peptide-resin was deprotected with piperidine/DMF 
(1:4, 1+20 min), then acetylated with acetic anhydride/DIEA (1:2) in DMF for 1 h. The peptide-resin was next treated 
with 1% TFA/CH2Cl2 to remove the Mmt group, neutralized with 5% DIEA/CH2Cl2, then chloroacetic acid (24 mg, 
250 mol, 5 equiv) was coupled with DIPCI (39 L, 250 mol, 5 equiv) activation in CH2Cl2 for 1 h. Deprotection 
and cleavage of the peptide-resin, followed by HPLC purification and lyophilization, were as above. Next, purified 
Fmoc-Lys(chloroacetyl)Tat (2 mg, 1 mol) was dissolved in 5 mL of 20 mM ammonium bicarbonate, pH 7.2, and 
reacted with 32 L of a 65 mM methanolic solution of 1 (2 mol), and the reaction mixture was stirred at 30 ºC until 
HPLC analysis showed no further progress. At that point, the reaction was quenched by addition of 5 mL of 10% 
HOAc, then purified by HPLC and lyophilized to give 0.9 mg of conjugate 8, amounting to 35% yield in the thioether 
formation and purification steps. 8 was characterized by analytical HPLC and MS (Figures S5 and S6, Supporting 
Information).  
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 Parasites and macrophages  
Leishmania donovani wild-type (MHOM/ET/67/L82) and MT-resistant (MHOM/ET/67/L82R40, kindly provided by 
Prof. S. L. Croft; London School of Hygiene and Tropical Medicine) promastigotes were grown at 25 °C in RPMI 
medium supplemented with 10% heat-inactivated fetal calf serum, gentamicin, penicillin, and 2 mM glutamine. The 
R40 MT-resistant phenotype was maintained by adding 40 µM MT to the growth medium. Before each assay, 
parasites were harvested at late exponential phase and washed twice in Hanks balanced salt solution supplemented 
with 10 mM D-glucose (pH 7.2) (HBSS-Glc). 
Peritoneal macrophages were elicited in 8 week-old Balb/C mice (animal facility, Centro de Investigaciones 
Biológicas, Madrid) by intra-peritoneal injection of sodium thioglycolate. Three days later macrophages were 
harvested by peritoneal washing with Hanks buffer and washed in the same medium, then seeded onto 14 mm–
diameter circular coverslides (Thermo Scientific, Braunschweig, Germany) as described(Luque-Ortega et al., 2012). 
Procedures were approved by the animal welfare committee of the center.  
 
Intracellular uptake and distribution of fluorescent MT analogues.  
Leishmania R40 promastigotes were resuspended at 2 × 10
7
 cells/mL in HBSS-Glc plus Hoechst 3342 (10 µg/mL 
final concentration). After 1 h, Quasar 670-Lys(Cys-S-BDP-MT)Tat (7) and Ac-Lys(COCH2-S-BDP-MT)Tat (8), 
were added at 2.5 µM final concentration and fluorescence observed up to 3 h on a TCS-SP2-AOBS-UV ultraspectral 
confocal microscope (Leica Microsystems, Heidelberg, Germany) without fixation(Luque-Ortega et al., 2012).  
BALB/c peritoneal macrophages seeded on circular coverslides (50,000 cells/coverslide) were incubated with 
conjugate 7 at a final concentration of 4 µM in RPMI-1640 devoid of phenol red, for 1 h at 37 ºC. Cells were washed 
three times with 1 mL of the same medium supplemented with 10 mg/mL of fatty acid-free BSA (Sigma) to remove 
non-incorporated conjugate, and incubated in the same medium for an additional 2 h to allow redox release of the 
drug from Tat. Cells were next incubated for 20 min with Hoechst 3422 and observed in a TCS-SP2-AOBS-UV 
confocal microscope (Leica) without fixation. For Hoechst 3342, BDP and Quasar exc and m were 350/460, 488/520 
and 644/670 nm, respectively. 
 
Cytotoxicity 
To determine parasite viability, R40 promastigotes were seeded in full growth medium devoid of phenol red at 2 × 
10
6
 cells/mL. Tat(48-60), Quasar 670-Lys(Cys-S-BDP-MT)Tat (7) and Ac-Lys(COCH2-S-BDP-MT)Tat (8), 
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dissolved in the same buffer, were added at the corresponding concentrations to the parasite suspension. Parasites 
were allowed to proliferate for 72 h at 26 ºC. Parasite viability was measured by inhibition of 3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium bromide (MTT, 0.5 mg/mL final concentration) reduction (Luque-Ortega et al., 2012). 
The insoluble formazan product was solubilized with 5% (w/v) SDS and detected at 600 nm with a Bio-Rad model 
640 microplate reader.   
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Results and discussion 
Design and synthesis of HS-BDP-MT (1).  
Insertion of fluorescent or other reactive groups into linear chain phospholipids may perturb the polarity balance and 
conformation of the original amphipathic structure, hence impair recognition and transport of the modified 
phospholipid at the cell level, with ensuing loss of bioactivity. In the present case our target was an MT analogue with 
a reporter fluorochrome, a distal thiol reacting group and minimal perturbation of the leishmanicidal properties of the 
original drug. Previous experience on alkylphosphocholine analogues showed that placing a lipophilic BDP group in 
the alkyl chain, well separated from the essential phosphocholine polar head-group, might led to compounds with 
antiparasitic properties similar to those of MT(Hornillos et al., 2010; Hornillos et al., 2008; Hornillos et al., 2006). 
We also assumed that a three-methylene spacer between the thiol and the BDP group would suffice to preserve thiol 
reactivity and facilitate conjugation. These considerations led to HS-BDP-MT (1), where the lipophilic part, 
consisting of 11 methylene spacers and the BDP fluorochrome, is of similar length as the C16 chain of MT.  
The synthesis of 1 involved four main steps (Scheme 2, see also Supporting Information, Scheme S1 and subsequent 
text). Non-symmetric BDP 4 was prepared by MacDonald condensation (Wood and Thompson, 2007) between -H-
pyrrole 2 and -formylpyrrole 3, both substituted at the 4-position with ω-hydroxyalkyl and ω-bromoalkyl residues, 
respectively, followed by in situ reaction with BF3·OEt2 in the presence of base. Substitution of the bromide in BDP 4 
with the sodium salt of 2-quinolinethiol gave the protected thiol 5 with hydrolysis of the trifluoroacetoxy 
group.(Zhang and Matteucci, 1999) Next, the phosphocholine head-group was introduced in the terminal alcohol by 
reaction with 2-chloro-1,3,2-dioxaphospholane-2-oxide in the presence of trimethylamine, yielding 6. Finally, the 
thiol protecting group was successfully cleaved off under mild conditions (Nakamura et al., 2002; Zhang and 
Matteucci, 1999) by reduction with sodium cyanoborohydride in acetic acid, without affecting the BDP fluorophore 
(sensitive to strong acids, bases or hydrogen) or the phosphocholine group. The overall yield of the target compound 
1 was 33%. All spectroscopic data confirmed the molecular structure of 1. The analogue is stable for months at 20 
ºC in solid form or in ethanol solution, under an inert atmosphere. 
 
Tat conjugates for BDP-MT internalization  
For delivery and visualization of the BDP-labeled MT analogue 1, it was linked to the Tat(48-60) CPP by two 
different strategies (Scheme 1). The common precursor in both approaches, a Tat(48-60) peptide-resin with an 
additional –Mmt protected Lys residue at the N-terminus (Scheme 3), was further elaborated in two different ways. 
(i) A disulfide-linked version of the Tat conjugate of 1, Quasar 670-Lys(Cys-S-BDP-MT)-Tat (7, Scheme 3, top) 
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displayed an additional labeling of the Tat moiety by Quasar 670, an indocarbocyanine dye that fluoresces in the red 
region of the visible spectrum (exc = 644 nm; em = 670 nm), similar to Cy™5. The rationale for the dual labeling 
was that a redox-scissile conjugate would facilitate visualization and localization of both MT and Tat moieties upon 
translocation and intracellular reductive cleavage. The orthogonal protection scheme of the Fmoc-Lys(Mmt)-Tat(48-
60) peptide-resin enabled selective deprotection and coupling of Quasar 670 at the N-terminal -amino group, 
followed by again selective deprotection-elongation at the Lys -amino group with a residue of Cys whose thiol 
function was protected-activated with an Npys group (Bernatowicz et al., 1986; Mezo et al., 2000; Ridge et al., 1982) 
to allow subsequent disulfide formation. The resulting Quasar 670-Lys[Cys(Npys)]Tat peptide intermediate was 
obtained upon acid deprotection/cleavage of the peptide-resin, purified by HPLC, then chemoselectively reacted with 
thiol 1 in a mildly acidic water-methanol medium where heterodisulfide 7 formation (60% yield after purification) 
prevailed upon thiol 1 oxidation/dimerization. (ii) In similar fashion, a thioether version of the conjugate also used 
Fmoc-Lys(Mmt)-Tat(48-60)-resin as precursor. A simpler labeling scheme with 1 as single fluorochrome was chosen 
in this case, as the reductively non-scissile nature of thioether 8 made dual labeling superfluous. Thus, the peptide-
resin was capped with an Ac group at the N-terminal -amino group, and the Lys -amino group was then elongated 
with a chloroacetyl (ClAc) group. TFA acidolysis gave a Fmoc-Lys(ClAc)Tat(48-60) intermediate that, after HPLC 
purification, underwent nucleophilic substitution by thiol 1 to give Ac-Lys(COCH2S-BDP-MT)Tat (8). The yield of 
thioether formation (35% after purification) was lower than for 7, reflecting the limited selectivity of the reaction, 
where substitution competes with thiol dimerization and with Cl displacement in the ClAc group by hydroxyl from 
the solvent (Monso et al., 2012).  
 
Tat-mediated delivery of MT into Leishmania and macrophages 
A thorough evaluation of the intracellular delivery of BDP-MT into Leishmania by conjugates 7 and 8 has been 
reported elsewhere (Luque-Ortega et al., 2012) and is only recapped here. First, a cytotoxic effect of 7 and 8 on both 
promastigote (Figure 1) and macrophage-infecting amastigote forms of the MT-resistant R40 strain of L. donovani 
was verified, proving the intracellular delivery of BDP-MT, hence the reversal of the resistant condition of the 
parasites. Second, 7 and 8 were both internalized to a similar extent regardless of disulfide or thioether linkage 
between Tat and BDP-MT (Scheme 1 and Figure 1). Sagan et al. have shown that disulfide exchange reactions with 
cell surface thiols can hamper the entry of disulfide-bearing CPPs (Aubry et al., 2009). Any concerns about conjugate 
7 in this regard were not verified; indeed, its uptake in intact form was also indirectly demonstrated by the segregate 
localization –evidencing post-uptake reductive release– of selectively labeled BDP-MT and Quasar 670-Tat moieties 
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after incubation for 3 h (Figure 2). Third, the efficient internalization of thioether-linked 8 also showed that a scissile 
BDP-MT moiety is not mandatory for leishmanicidal activity (Figure 1). 
In Leishmania-infected macrophages, MT accumulates mainly in intracellular parasites, hence accounting for 
leishmanicidal activity, while uptake in the cytoplasm is much lower (Luque-Ortega et al., 2012). For non-infected 
macrophages, despite their usually high endocytic rates, MT (1) uptake is also poor (Figure 3, lower panels). It 
seemed thus reasonable to investigate whether Tat conjugation as in 7 and 8 might promote uptake even in the 
absence of parasite infection. Indeed, when Tat-bound as in 7, BDP-MT showed outstanding incorporation (Figure 3, 
upper panels). Also, areas of predominantly green (BDP-MT) or red (Quasar-Tat) fluorescence could be 
distinguished, accounting as in the Leishmania case for reductive cleavage of the conjugate followed by distribution 
of the resulting moieties in the macrophage cytoplasm. This strongly suggested that Tat-mediated uptake can expand 
the range of MT targets to include non-transformed cell types.  
For Leishmania, amastigote survival and replication within the macrophage are known to rely on activation of various 
host cell survival pathways upon parasite infection, PI3K/Akt being one of the most notorious (Ruhland et al., 2007). 
This kinase, in turn, is inhibited by alkyl-lysophospholipids, (reviewed in (van Blitterswijk and Verheij, 2013)) which 
as we have just seen can only be efficiently internalized by conjugation to a CPP. Hence, Tat-mediated MT delivery 
opens up new possibilities of tackling parasitic diseases such as leishmaniasis by modulation of host cell uptake 
preferences instead of straightforward action on the parasite. In this context, an obvious hurdle is to ensure specific 
drug action by equally specific MT delivery to a particular cell type target. For macrophages, this could be solved by 
conjugate encapsulation, taking advantage of the high endocytic rate of these cells. For other cell types, alternative 
strategies are envisaged such as CPPs with variable degrees of cell selectivity, or standard CPPs endowed with 
homing peptide sequences that bias conjugate distribution into specific cell types (reviewed in (Svensen et al., 2012)).  
 
Concluding remarks 
This work addresses two important issues in drug delivery: (i) the need for fluorescent versions of useful 
pharmaceuticals, to monitor their cell uptake and distribution, and (ii) expanding the spectrum of cell types 
susceptible to a given drug. MT, the subject of our study, posed an additional requirement for minimal structural 
alteration to ensure that antiparasitic action was preserved.   
The first issue has been solved by means of HS-BDP-MT (1), an analogue with an embedded BDP group conferring 
the desired fluorescent properties, and a thiol group enabling conjugation. The intrinsic structural features of 1 
prevented the use of FRET or other strategies to visualize the intracellular splitting of the BDP-MT and Tat moieties 
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of the disulfide conjugate and their resulting subcellular distribution. However, an additional, non-overlapping 
fluorochrome placed on the Tat peptide successfully allowed to track the cleavage.  
As to the second issue, the present work is to our best knowledge the first example of MT conjugation to a CPP, with 
the ensuing expansion in the range of susceptible cells, so far confined to tumoral phenotypes and lower eukaryotes. 
Our results with mouse macrophages, serving not only as primary cell models but most importantly as host cells that 
undergo extensive functional retooling by Leishmania, provide the required proof of mechanism and suggest several 
potential application strategies: (i) treating simultaneously MT targets in both the parasite and the host cell; (ii) 
treating Leishmania-specific targets which the parasite secretes into the macrophage; delivering drugs against these 
targets through the macrophage –a professional phagocyte– membrane is arguably easier than through the sturdy 
Leishmania membrane; (iii) extrapolation to other macrophage intracellular pathogens such as Mycobacterium or 
Legionella with high impact on human health. 
 
 
Acknowledgements 
Research supported by funds from the European Union (HEALTH-2007-223414 to L.R. and D.A.), Fondo de 
Investigaciones Sanitarias (RD 06/0021/0006, RD12/0018/0007, PI09-01928, PI12-02706 to L.R.), MICINN 
(CTQ2010-16457 to A.U.A, BIO2008-04487-CO3 to D.A.), MINECO (SAF2011-24899 to D.A.) and Generalitat de 
Catalunya (SGR2009-00492 to D.A.). 
 
Supplementary information 
 Synthesis of pyrroles 2 and 3, carbon numbering of MT analogue 1 and precursors; 
1
H- and 
13
C-NMR spectra of 1; 
HPLC and mass spectra of conjugates 7 and 8.  
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
GRKKRRQRRRPPQ
O
HN
NH
N
O
N
O
H2N
S
N
B
N
FF
S O P O
N
O
O3 8
N
B
N
FF
HS O P O
N
O
O3
GRKKRRQRRRPPQ
Tat(48-60), a cell-penetrating peptide
Reduction-sensitive, dual fluoro label
1 (HS-BDP-MT)
A miltefosine analog with in-built fluorolabel
[(Quasar 670-Lys(Cys-S-BDP-MT)Tat)
GRKKRRQRRRPPQ
O
Ac-HN
NH
O
N
B
N
FF
S O P O
N
O
O3 8
Reduction-stable, single fluoro label
8 (Ac-Lys(COCH2S-BDP-MT)Tat)
Cell-penetrating Tat peptide
8
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 1   
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
  
 
Scheme 2. Reagents and conditions: (i) POCl3, CH2Cl2, Ar, 5 h, then DIPEA, BF3.OEt2, 25 min, 85%; (ii) 2-quinolinethiol, MeONa/MeOH, reflux, 2 h, 95%; (iii) 2-chloro-
1,3,2-dioxaphospholane-2-oxide (2 equiv.), Me3N, MeCN, Ar, pressure tube, 78 ºC, then room temp., 3 h, then 80 ºC, 4 h, 43%; (iv) NaBH3CN, HOAc, room temp, 2 h, 
then H2O, 1 h, 94% 
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Scheme 3. Reagents and conditions: (i) piperidine/DMF (1:4), 1 + 20 min, then Quasar 670 carboxylic 
acid, DIPCI (3 equiv), CH2Cl2, 1 h; (ii) TFA/CH2Cl2, (1%), then Boc-Cys(Npys)-OH, DIPCI (3 equiv 
each), CH2Cl2, 1 h, then TFA/H2O/TIS (95:2.5:2.5 v/v), 90 min, HPLC purification; (iii) pH 5, then 1 (1 
equiv) in methanol, HPLC purification; (iv) piperidine/DMF (1:4), 1 + 20 min, then Ac2O/DIEA (2:1) in 
DMF, 30 min, then TFA/CH2Cl2 (1%), then ClCH2COOH/DIPCI, (5 equiv each), CH2Cl2, 1 h, then 
TFA/H2O/TIS (95:2.5:2.5 v/v), 90 min, HPLC purification; (v) 20 mM ammonium bicarbonate, pH 7.2, 
then 1 (1 equiv) in methanol, 30 ºC, HPLC purification. 
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Figure captions 
Figure 1. Tat conjugation overcomes MT resistance in R40 L. donovani promastigotes. Inhibition of R40 
proliferation by compound 1 (black bars), conjugate 7 (empty bars), conjugate 8 (green bars), Tat(48-60) 
(blue bars) and Tat(48-60) + 1 (1:1molar ratio, red bars).   
 
Figure 2. Intracellular distribution of conjugate 7 in L. donovani R40 parasites. Cells were pre-stained with 
Hoechst 3342  and incubated with 2.5 µM conjugate for 5 min (A) or 3 h (B), then observed unfixed by 
confocal microscopy. exc and em were 350/460 nm for Hoechst 3342; 488/520 nm for BDP and 644/670 
for Quasar 670.  Bar =10 µm 
 
Figure 3. Effect of Tat conjugation on BDP-MT internalization in macrophages. Balb/C mice peritoneal 
macrophages were treated with either conjugate 7 (upper panels) or non-conjugated 1 (lower panels) at 4 
µM. Cells were incubated at 37 ºC for 1 h, washed and incubated for an additional 2 h. 20 min prior to 
observation, Hoechst 3342 (10 µg/mL) was added to localize the nucleus.  exc and em were 644/670 for 
Quasar 670, 488/520 nm for BDP and 350/460 nm for Hoechst 3342.  Bar= 10 µm.  
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